Basic Mechanisms and Model Systems in Lysosomal Disorders
Lysosomal & Rare Disorders Research & Treatment Center
GRIDS-2022
Basic Mechanisms and Model Systems in Lysosomal Disorders
January 23, 2023 – January 23, 2024
Estimated time to complete: 1.25 hours
NO LONGER AVAILABLE FOR CREDIT
Continuing Education Information
This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.
Speakers
Mia Horowitz, PhD, Tel Aviv University, Israel
Ricardo Feldman, PhD, University of Maryland
Andrés D. Klein, PhD, Instituto de Ciencias e Innovación en Medicina (ICIM), Chile
Disclosures
AffinityCE staff, LDRTC staff, CheckRare staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and will be stated prior to the start of each session.
Faculty disclosures
Mia Horowitz, PhD, Tel Aviv University, Israel
IIR: Pfizer, Takeda
No discussion of unapproved drug or product uses.
Ricardo Feldman, PhD, University of Maryland
No relevant financial arrangements with ineligible companies to disclose.
No discussion of unapproved drug or product uses.
Andrés D. Klein, PhD, Instituto de Ciencias e Innovación en Medicina (ICIM), Chile
No relevant financial arrangements with ineligible companies to disclose.
No discussion of unapproved drug or product uses.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.
Learning Objectives
At the end of this activity, participants should be able to address one or more of the following:
- Review how models are used to test treatment efficacy
- Review model systems used in Niemann-Pick type C
- Review model systems used in Gaucher disease.
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 1.25 hours of continuing nursing education credit.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Genetic Counselors
Category 2 CEU
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Commercial Support
Educational grant support for GRIDS 2022 provided by Sanofi Genzyme, Takeda Pharmaceutical Company, Chiesi USA, Amicus Therapeutics, and BioMarin.
Participation Costs
There is no cost to participate in this activity.
CME Inquiries
For all CME policy-related inquiries, please contact us at [email protected].
Send customer support requests to [email protected].
